News & Updates
Filter by Specialty:
Secukinumab safe, effective in children with moderate to severe plaque psoriasis
Treatment with either low- or high-dose secukinumab is effective and well tolerated in paediatric patients with moderate to severe plaque psoriasis, a study has shown.
Secukinumab safe, effective in children with moderate to severe plaque psoriasis
31 Jan 2022Depression rife in hidradenitis suppurativa
The prevalence of depression is relatively high among children, adolescents, and adults with hidradenitis suppurativa (HS), a chronic inflammatory skin disorder, according to a study, which also notes the importance of periodic screening for depression.
Depression rife in hidradenitis suppurativa
23 Jan 2022PSOARING trials boost potential of tapinarof for plaque psoriasis
The nonsteroidal topical aryl hydrocarbon receptor (AHR)-modulating agent tapinarof 1% trumped a vehicle control cream in reducing the severity and manifestations of plaque psoriasis, according to the phase III PSOARING 1 and 2 trials.
PSOARING trials boost potential of tapinarof for plaque psoriasis
21 Jan 2022Atopic dermatitis in children show high endotype heterogeneity
Paediatric atopic dermatitis shows four distinct clusters of serum biomarker profiles, only one of which shows marked similarity to adult biomarker clusters, a recent study has found.
Atopic dermatitis in children show high endotype heterogeneity
11 Jan 2022Changes in MetS diagnosis affects psoriasis risk
The risk of psoriasis is elevated in patients with continuous metabolic syndrome (MetS) and in those with newly developed MetS, a recent study has found. In contrast, such risk is absent in individuals with only a history of MetS.
Changes in MetS diagnosis affects psoriasis risk
28 Dec 2021Depression prevalent in children, adults with hidradenitis suppurativa
Depression is not uncommon among children, adolescents, and adults with hidradenitis suppurativa (HS), reports a study, adding that periodic screening for depression may be necessary.